axicabtagene ciloleucel

This page shows the latest axicabtagene ciloleucel news and features for those working in and with pharma, biotech and healthcare.

Gilead optimistic about Yescarta deal in UK

Yescarta (axicabtagene ciloleucel) and its rival CAR-T therapy Novartis’Kymriah (Tisagenlecleucel-T) were granted European approved on the same day in relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Latest news

Novartis’ CAR-T Kymriah gets green light in England

The rapid agreement on Kymriah is in stark contrast to NICE’s speedy rejection in draft guidance of Gilead/Kite Pharma’s rival CAR-T Yescarta (axicabtagene ciloleucel), which was approved
It’s a no for Yescarta, says NICE on heels of EU approval

The appraisal document for Yescarta (axicabtagene ciloleucel ) notes that the therapy “is not recommended, within its anticipated marketing authorisation, for treating relapsed or refractory diffuse large B-cell lymphoma or primary ... While Yescarta
MaxCyte gets green light for solid tumour cell therapy

The current generation of CAR-T therapies – namely Novartis’Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) – use engineered T cells harvested from blood, which have to be expanded in
CAR-Ts Kymriah and Yescarta step closer to approval in Europe

However the EMA has been working on its own fast-track for the most important new drugs, the PRIority MEdicines (PRIME) scheme, and Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) are the
New trial results suggest CAR-T effects are durable in lymphoma

Yescarta (axicabtagene ciloleucel or axi-cel) which was approved for that indication the previous October and made $40m in the first quarter, ahead of the $16m predicted by analysts.

More from news
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest Intelligence

The European Medicines Agency: PRIME’d for access?

Early signs are looking good: Novartis’Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June
Deal Watch January 2017

Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Market Access Consultant - Greater Manchester: Negotiable

Systematic Review Lead- London: Negotiable

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Writer, Healthcare Advertising, London: Excellent package

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Healthcare PR Director: £100, 000 – £120, 000 benefits

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Account Manager- 4 days per week or full-time: Salary TBC

Senior Training Manager - Surrey: Competitive Salary &Bonus

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Graduate Scientific Editor: DOE

Associate Scientific Director: Salary TBC

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Medical Writer - Creative and Scientific Projects: DOE

Account Manager: Negotiable

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Subscribe to our email news alerts

PMHub

Add my company

3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....